OSTEOPORE LIMITED — Capital/Financing Update 2020

Aug 20, 2020

==> picture [130 x 44] intentionally omitted <==

ASX RELEASE│OSTEOPORE LIMITED

OSTEOPORE RECEIVES BINDING COMMITMENTS FOR $8.5M PLACEMENT

21 August 2020: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), a revenue generating medical technology company that has commercialised a range of patented 3D printed bioresorbable products, is pleased to announce that it has received binding commitments from institutional and sophisticated investors to raise AUD8.5m (before costs) through a single tranche placement ("Placement").

The Placement was supported by a number of the Company’s existing shareholders and introduced a number of new, high net-worth investors and institutions to the Osteopore register. The Company worked diligently to ensure new investors were aligned with its continued growth strategy.

Funds will be utilised for further business development focused on growing the Company’s existing revenue base, and supporting ongoing clinical trials for dental and orthopaedic applications of the Osteopore technology. The funds will also assist the Company with ongoing development of second generation products and complementary technologies and opportunities that support the core Osteopore business strategy. Together with existing cash reserves, the Placement ensures OSX is well funded to increase revenue from current geographic territories and expand manufacturing capability to meet future demand. The funding will also allow the company to build market penetration through its existing distributor network and establish new geographic markets in Australia, Europe, US and Asia.

The Placement will result in the issue of 16,037,736 new ordinary shares at an issue price of $0.53 per share. Settlement of the Placement is expected to occur on 26 August 2020, with the issue and trading of Placement Shares expected to commence on 27 August 2020.

The issue price represents a discount of 13.1% to the last traded price of $0.61 and a 15.4% discount to the 15-day volume weighted average share price.

The Placement will be made under Osteopore’s existing placement capacities under ASX Listing Rule 7.1 (12,184,575 Shares) and 7.1A (3,853,161 Shares) and does not require shareholder approval. The new shares issued under the Placement will rank pari-passu with the existing fully paid ordinary shares in the Company.

E&P Corporate Advisory Pty Ltd and ACNS Capital Markets Pty Ltd (“Alto Capital”) acted as Joint Lead Managers to the Placement. In addition to the Placement Shares, the Company will issue 3,000,000 options exercisable at $1.20 and expiring August 2023 to the Joint Lead Managers (to be issued under the Company’s existing capacity under ASX Listing Rule 7.1).

This announcement has been approved for release by the Board of Osteopore.

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com

==> picture [130 x 44] intentionally omitted <==

For more information please contact:

Geoff Pocock Executive Director Osteopore Limited +61 4 1219 4373 geoff_pocock@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent protected scaffolds are made from proprietary polymer formulations, that naturally dissolve overtime to leave only natural. healthy bone tissue, significantly reducing postsurgery complications that are commonly associated with permanent bone implants.

Osteopore Limited (ACN 630 538 957)│ASX:OSX│16 Ord Street, West Perth│+618 9482 0500│www.osteopore.com